{"schemaVersion":"maha-epistemic/1.0","evidencePolicyVersion":"mps/0.1","generatedAt":"2026-08-24T00:00:00.000Z","domain":{"slug":"synthetic-biology","name":"Synthetic biology and cellular engineering","description":"Molecular tools, cell systems, protocols, measurements, and safety boundaries represented with explicit experimental scope.","stressPoint":"Performance in a cell line, organoid, animal model, and human intervention are different evidence states and cannot be silently collapsed.","accent":"green"},"lifecycle":{"status":"active-structured-domain","foundationalTarget":23,"canonicalFactoryRecords":23,"outstandingFactoryRecords":0},"counts":{"graphRecords":25,"graphEdges":30,"publicCanonicalRecords":24,"withheldRecords":1},"records":[{"id":"urn:maha:record:cell-line-versus-primary-cell-evidence","title":"Cell-line versus primary-cell evidence","recordKind":"comparison","reviewState":"published-canonical","canonicalPath":"/knowledge/synthetic-biology/comparisons/cell-line-versus-primary-cell-evidence","contentHash":"sha256:d3a5240fcb9425c41d5687b231e1d31a9194ad969d066dbd1e0a8d4772c3a392","claims":[{"id":"urn:maha:claim:cell-line-versus-primary-cell-evidence","scope":"The constructs, biological systems, protocols, assays, datasets, and comparisons reported in CHANGE-seq reveals genetic and epigenetic effects on CRISPR–Cas9 genome-wide activity.","boundary":"Results from a transformed line cannot be silently relabeled as performance in primary cells, and donor variation remains a separate uncertainty source.","claimKind":"empirical-claim","sourceIds":["source-lazzarotto-change-seq-2020"],"statement":"The cited study measures and compares off-target activity and genomic context in therapeutically relevant loci and primary human T-cell experiments.","replication":{"asOfDate":"2026-08-24","assessment":"This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-lazzarotto-change-seq-2020","url":"https://www.nature.com/articles/s41587-020-0555-7","title":"CHANGE-seq reveals genetic and epigenetic effects on CRISPR–Cas9 genome-wide activity","rights":{"note":"Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Christopher R. Lazzarotto","Nhu T. Nguyen","J. A. Tangprasertchai","S. C. Malagon-Lopez","et al."],"boundary":"In-vitro nomination is not identical to editing frequency or biological consequence in a treated cell population or organism.","publisher":"Nature Biotechnology","establishes":"The study develops an in-vitro circularized-DNA assay for Cas9 activity and compares nominations with cellular activity and genomic context for specified targets.","identifiers":[{"value":"10.1038/s41587-020-0555-7","scheme":"doi"}],"publishedAt":"2020-06-22","exactLocator":"Abstract; Figures 1–6; Methods; datasets PRJNA625995 and GSE149295.","conflictsOfInterest":"The article declares patent and company relationships involving genome-editing assays and therapeutics."}],"boundaries":["Results from a transformed line cannot be silently relabeled as performance in primary cells, and donor variation remains a separate uncertainty source.","A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record."],"prohibitedInferences":["Do not treat the cell-line versus primary-cell evidence record as medical advice, a treatment recommendation, or evidence of general clinical readiness.","Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract."]},{"id":"urn:maha:record:in-vitro-versus-in-vivo-evidence","title":"In-vitro versus in-vivo evidence","recordKind":"comparison","reviewState":"published-canonical","canonicalPath":"/knowledge/synthetic-biology/comparisons/in-vitro-versus-in-vivo-evidence","contentHash":"sha256:1f458c5ae7945d793266f1755a6dd204d3d1f1b4eb1e48624cc5be91bf142f0e","claims":[{"id":"urn:maha:claim:in-vitro-versus-in-vivo-evidence","scope":"The constructs, biological systems, protocols, assays, datasets, and comparisons reported in CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.","boundary":"In-vivo evidence is still intervention-, tissue-, dose-, population-, endpoint-, comparator-, and follow-up-specific and does not become universal.","claimKind":"empirical-claim","sourceIds":["source-gillmore-in-vivo-2021"],"statement":"The cited phase 1 study measures delivery-linked editing effects and early observations in human participants rather than inferring them from an in-vitro assay.","replication":{"asOfDate":"2026-08-24","assessment":"This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-gillmore-in-vivo-2021","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2107454","title":"CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis","rights":{"note":"Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Julian D. Gillmore","Ed Gane","Julian Taubel","Jingzhu Kao","et al."],"boundary":"Early biomarker and safety observations do not establish long-term clinical benefit, rare-event safety, or transfer to other tissues and targets.","publisher":"The New England Journal of Medicine","establishes":"The phase 1 report describes systemic lipid-nanoparticle delivery of CRISPR components and early dose-cohort biomarker and safety observations in adults with transthyretin amyloidosis.","identifiers":[{"value":"10.1056/NEJMoa2107454","scheme":"doi"}],"publishedAt":"2021-06-26","exactLocator":"Abstract; Methods; Results; Figures 1–3; supplementary protocol and statistical analysis.","conflictsOfInterest":"The study was funded by Intellia Therapeutics and Regeneron Pharmaceuticals; author relationships are disclosed."}],"boundaries":["In-vivo evidence is still intervention-, tissue-, dose-, population-, endpoint-, comparator-, and follow-up-specific and does not become universal.","A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record."],"prohibitedInferences":["Do not treat the in-vitro versus in-vivo evidence record as medical advice, a treatment recommendation, or evidence of general clinical readiness.","Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract."]},{"id":"urn:maha:record:off-target-nomination-versus-confirmation","title":"Off-target nomination versus confirmation","recordKind":"comparison","reviewState":"published-canonical","canonicalPath":"/knowledge/synthetic-biology/comparisons/off-target-nomination-versus-confirmation","contentHash":"sha256:4a1ca166e9fa96cd9fb93104466f3af46e3535a5d03348edcdc2fa1ee5b617f5","claims":[{"id":"urn:maha:claim:off-target-nomination-versus-confirmation","scope":"The constructs, biological systems, protocols, assays, datasets, and comparisons reported in CHANGE-seq reveals genetic and epigenetic effects on CRISPR–Cas9 genome-wide activity.","boundary":"A nominated site is not automatically edited in cells, while a non-nominated site is not proof of absolute absence below every detection limit.","claimKind":"empirical-claim","sourceIds":["source-lazzarotto-change-seq-2020"],"statement":"The cited study compares in-vitro CHANGE-seq nominations with cellular off-target activity and shows that genomic context and individual variation affect correspondence.","replication":{"asOfDate":"2026-08-24","assessment":"This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-lazzarotto-change-seq-2020","url":"https://www.nature.com/articles/s41587-020-0555-7","title":"CHANGE-seq reveals genetic and epigenetic effects on CRISPR–Cas9 genome-wide activity","rights":{"note":"Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Christopher R. Lazzarotto","Nhu T. Nguyen","J. A. Tangprasertchai","S. C. Malagon-Lopez","et al."],"boundary":"In-vitro nomination is not identical to editing frequency or biological consequence in a treated cell population or organism.","publisher":"Nature Biotechnology","establishes":"The study develops an in-vitro circularized-DNA assay for Cas9 activity and compares nominations with cellular activity and genomic context for specified targets.","identifiers":[{"value":"10.1038/s41587-020-0555-7","scheme":"doi"}],"publishedAt":"2020-06-22","exactLocator":"Abstract; Figures 1–6; Methods; datasets PRJNA625995 and GSE149295.","conflictsOfInterest":"The article declares patent and company relationships involving genome-editing assays and therapeutics."}],"boundaries":["A nominated site is not automatically edited in cells, while a non-nominated site is not proof of absolute absence below every detection limit.","A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record."],"prohibitedInferences":["Do not treat the off-target nomination versus confirmation record as medical advice, a treatment recommendation, or evidence of general clinical readiness.","Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract."]},{"id":"urn:maha:record:somatic-versus-germline-editing","title":"Somatic versus germline genome editing","recordKind":"comparison","reviewState":"published-canonical","canonicalPath":"/knowledge/synthetic-biology/comparisons/somatic-versus-germline-editing","contentHash":"sha256:93822d3f525b540db478076159aa36c1e561ef78b3dba595b81a9ada824258ee","claims":[{"id":"urn:maha:claim:somatic-versus-germline-editing","scope":"The constructs, biological systems, protocols, assays, datasets, and comparisons reported in CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes.","boundary":"The experiment does not establish safe or acceptable reproductive use; germline questions require distinct ethical, legal, clinical, and multigenerational evidence.","claimKind":"empirical-claim","sourceIds":["source-liang-embryo-editing-2015"],"statement":"The cited embryo study reports mosaic and unintended outcomes after CRISPR-Cas9 exposure of non-viable tripronuclear human zygotes.","replication":{"asOfDate":"2026-08-24","assessment":"This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-liang-embryo-editing-2015","url":"https://link.springer.com/article/10.1007/s13238-015-0153-5","title":"CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes","rights":{"note":"Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Puping Liang","Yanwen Xu","Xiya Zhang","Chenhui Ding","et al."],"boundary":"The experiment does not establish reproductive safety, heritable clinical benefit, ethical acceptability, or authorization for germline use.","publisher":"Protein & Cell","establishes":"The study reports CRISPR-Cas9 editing outcomes, mosaicism, and unintended events in non-viable tripronuclear human zygotes under the stated protocol.","identifiers":[{"value":"10.1007/s13238-015-0153-5","scheme":"doi"}],"publishedAt":"2015-04-18","exactLocator":"Abstract; Results; Tables 1–2; Methods; ethical statement."}],"boundaries":["The experiment does not establish safe or acceptable reproductive use; germline questions require distinct ethical, legal, clinical, and multigenerational evidence.","A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record."],"prohibitedInferences":["Do not treat the somatic versus germline genome editing record as medical advice, a treatment recommendation, or evidence of general clinical readiness.","Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract."]},{"id":"urn:maha:record:adenine-base-editing","title":"Adenine base editing","recordKind":"concept","reviewState":"published-canonical","canonicalPath":"/knowledge/synthetic-biology/concepts/adenine-base-editing","contentHash":"sha256:b421e623b3590e7b4856e0d53bdfe8d1b596f012122618d0bc88a8acf0b86bd5","claims":[{"id":"urn:maha:claim:adenine-base-editing","scope":"The constructs, biological systems, protocols, assays, datasets, and comparisons reported in Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage.","boundary":"The source does not establish universal specificity, delivery, tissue performance, safety, or clinical benefit.","claimKind":"empirical-claim","sourceIds":["source-gaudelli-abe-2017"],"statement":"The cited study evolves adenine base editors and characterizes targeted A-to-G editing in specified experimental systems.","replication":{"asOfDate":"2026-08-24","assessment":"This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-gaudelli-abe-2017","url":"https://www.nature.com/articles/nature24644","title":"Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage","rights":{"note":"Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Nicole M. Gaudelli","Alexis C. Komor","Holly A. Rees","Michael S. Packer","et al."],"boundary":"Reported performance does not transfer automatically to other editors, guides, loci, cells, delivery systems, organisms, or clinical settings.","publisher":"Nature","establishes":"The study evolves and characterizes adenine base editors that install targeted A-to-G outcomes in specified bacterial and human-cell experiments.","identifiers":[{"value":"10.1038/nature24644","scheme":"doi"}],"publishedAt":"2017-11-01","exactLocator":"Abstract; Figures 1–5; Methods; Extended Data; Supplementary Information.","conflictsOfInterest":"The article declares patent applications and company interests involving base-editing technologies."}],"boundaries":["The source does not establish universal specificity, delivery, tissue performance, safety, or clinical benefit.","A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record."],"prohibitedInferences":["Do not treat the adenine base editing record as medical advice, a treatment recommendation, or evidence of general clinical readiness.","Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract."]},{"id":"urn:maha:record:crispr-cas9-nuclease-editing","title":"CRISPR-Cas9 nuclease editing","recordKind":"concept","reviewState":"published-canonical","canonicalPath":"/knowledge/synthetic-biology/concepts/crispr-cas9-nuclease-editing","contentHash":"sha256:d02ff1aefcb15c18eb0dceb3659d81e832cefd61968287ffa20b21a17a2c47af","claims":[{"id":"urn:maha:claim:crispr-cas9-nuclease-editing","scope":"The constructs, biological systems, protocols, assays, datasets, and comparisons reported in A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.","boundary":"Biochemical cleavage is not equivalent to efficient, specific, or safe genome editing in a cell or organism.","claimKind":"empirical-claim","sourceIds":["source-jinek-cas9-2012"],"statement":"The cited biochemical study reconstitutes programmable Cas9 cleavage and shows that a designed single guide can direct sequence-specific cutting adjacent to a compatible motif.","replication":{"asOfDate":"2026-08-24","assessment":"This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-jinek-cas9-2012","url":"https://www.science.org/doi/10.1126/science.1225829","title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","rights":{"note":"Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Martin Jinek","Krzysztof Chylinski","Ines Fonfara","Michael Hauer","Jennifer A. Doudna","Emmanuelle Charpentier"],"boundary":"An in-vitro nuclease mechanism does not establish editing efficiency, specificity, delivery, safety, or phenotype in cells or organisms.","publisher":"Science","establishes":"The study reconstitutes RNA-programmed Cas9 cleavage in vitro and shows that a designed single-guide RNA can direct sequence-specific DNA cleavage adjacent to an appropriate motif.","identifiers":[{"value":"10.1126/science.1225829","scheme":"doi"}],"publishedAt":"2012-06-28","exactLocator":"Abstract; Figures 1–5; supplementary materials describing guide design and cleavage assays."}],"boundaries":["Biochemical cleavage is not equivalent to efficient, specific, or safe genome editing in a cell or organism.","A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record."],"prohibitedInferences":["Do not treat the crispr-cas9 nuclease editing record as medical advice, a treatment recommendation, or evidence of general clinical readiness.","Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract."]},{"id":"urn:maha:record:cytosine-base-editing","title":"Cytosine base editing","recordKind":"concept","reviewState":"published-canonical","canonicalPath":"/knowledge/synthetic-biology/concepts/cytosine-base-editing","contentHash":"sha256:7b4a24ae0a546d04734e703118b455e2b4521d45c3a52924f1ad8b97168a2e34","claims":[{"id":"urn:maha:claim:cytosine-base-editing","scope":"The constructs, biological systems, protocols, assays, datasets, and comparisons reported in Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage.","boundary":"Reported activity windows, product purity, bystanders, indels, and off-target effects are editor- and context-specific.","claimKind":"empirical-claim","sourceIds":["source-komor-cbe-2016"],"statement":"The cited study constructs and tests cytosine base editors in specified transformed human and murine cell lines.","replication":{"asOfDate":"2026-08-24","assessment":"This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-komor-cbe-2016","url":"https://www.nature.com/articles/nature17946","title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","rights":{"note":"Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Alexis C. Komor","Yongjoo B. Kim","Michael S. Packer","John A. Zuris","David R. Liu"],"boundary":"The reported windows, efficiencies, byproducts, and indels are editor-, guide-, target-, cell-, delivery-, and assay-specific.","publisher":"Nature","establishes":"The study constructs cytosine base editors and reports targeted C-to-T conversion outcomes in specified transformed human and murine cell lines.","identifiers":[{"value":"10.1038/nature17946","scheme":"doi"}],"publishedAt":"2016-04-20","exactLocator":"Abstract; Figures 1–5; Methods; Extended Data; Supplementary Information.","conflictsOfInterest":"The article declares patent applications and company interests involving base-editing technologies."}],"boundaries":["Reported activity windows, product purity, bystanders, indels, and off-target effects are editor- and context-specific.","A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record."],"prohibitedInferences":["Do not treat the cytosine base editing record as medical advice, a treatment recommendation, or evidence of general clinical readiness.","Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract."]},{"id":"urn:maha:record:genetic-toggle-switch","title":"Genetic toggle switch","recordKind":"concept","reviewState":"published-canonical","canonicalPath":"/knowledge/synthetic-biology/concepts/genetic-toggle-switch","contentHash":"sha256:3ec5a44f869becdddcb4c3fe159c4090a18d83b01af48c5ded5fee13149394d1","claims":[{"id":"urn:maha:claim:genetic-toggle-switch","scope":"The constructs, biological systems, protocols, assays, datasets, and comparisons reported in Construction of a genetic toggle switch in Escherichia coli.","boundary":"The circuit’s memory and stability cannot be transferred to other hosts, copy numbers, growth conditions, burdens, or timescales.","claimKind":"empirical-claim","sourceIds":["source-gardner-toggle-2000"],"statement":"The cited study constructs a bistable toggle in Escherichia coli and reports switching thresholds and state behavior under defined induction conditions.","replication":{"asOfDate":"2026-08-24","assessment":"This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-gardner-toggle-2000","url":"https://www.nature.com/articles/35002131","title":"Construction of a genetic toggle switch in Escherichia coli","rights":{"note":"Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Timothy S. Gardner","Charles R. Cantor","James J. Collins"],"boundary":"Behavior in one bacterial construct and environment does not establish stability, safety, or equivalent function in other hosts and contexts.","publisher":"Nature","establishes":"The study constructs a mutually repressive bistable gene circuit in Escherichia coli and reports switching under specified inducer and temperature conditions.","identifiers":[{"value":"10.1038/35002131","scheme":"doi"}],"publishedAt":"2000-01-20","exactLocator":"Abstract; Figures 1–6; mathematical model and experimental switching results."}],"boundaries":["The circuit’s memory and stability cannot be transferred to other hosts, copy numbers, growth conditions, burdens, or timescales.","A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record."],"prohibitedInferences":["Do not treat the genetic toggle switch record as medical advice, a treatment recommendation, or evidence of general clinical readiness.","Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract."]},{"id":"urn:maha:record:prime-editing","title":"Prime editing","recordKind":"concept","reviewState":"published-canonical","canonicalPath":"/knowledge/synthetic-biology/concepts/prime-editing","contentHash":"sha256:c24c8f741970fba8f97b643116394886169715da3e20728f3d65b9302e55f40b","claims":[{"id":"urn:maha:claim:prime-editing-demonstration","scope":"The experiments, cell systems, loci, editor variants, assays, and comparisons reported in the founding Nature paper and its supplementary information.","boundary":"The experiments do not establish safe delivery, whole-organism efficacy, long-term clinical outcomes, or suitability for any individual treatment.","claimKind":"empirical-claim","sourceIds":["source-anzalone-prime-editing-2019"],"statement":"The 2019 founding study demonstrated targeted substitutions, insertions, and deletions using prime editors in four human cell lines and primary post-mitotic mouse cortical neurons, with efficiency varying by edit and system.","replication":{"asOfDate":"2026-08-24","assessment":"This Phase 1 record is deliberately bounded to the founding study and does not yet compile independent replication evidence.","independentReplicationCount":null},"uncertainty":{"kind":"quantitative","interval":"See experiment-level figures and supplementary tables; not pooled into one value.","statement":"The source reports experiment-specific means and variation; there is no single valid efficiency or error interval for prime editing across targets and biological systems."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-anzalone-prime-editing-2019","url":"https://www.nature.com/articles/s41586-019-1711-4","title":"Search-and-replace genome editing without double-strand breaks or donor DNA","rights":{"note":"The Maha page paraphrases the reported method and scope, links to the version of record, and reproduces no paywalled passage.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Andrew V. Anzalone","Peyton B. Randolph","Jessie R. Davis","Alexander A. Sousa","Luke W. Koblan","et al."],"boundary":"It is not clinical evidence, does not establish delivery to human tissues, and does not provide a universal safety or efficacy estimate for all prime-editor designs.","publisher":"Nature","establishes":"The paper introduces the prime-editing architecture and reports targeted edit classes across specified human cell lines and primary mouse neurons with experiment-dependent efficiencies and byproducts.","identifiers":[{"value":"10.1038/s41586-019-1711-4","scheme":"doi"},{"value":"PRJNA565979","scheme":"accession"}],"publishedAt":"2019-10-21","exactLocator":"Abstract; Figures 1–5; Methods; Extended Data; Supplementary Tables 1–5.","conflictsOfInterest":"The publisher record states that authors filed patent applications and identifies company relationships involving genome-editing technologies."}],"boundaries":["In-vitro or ex-vivo editing performance does not establish in-vivo delivery, safety, efficacy, or clinical benefit.","Efficiency and byproduct measurements are target-, editor-, protocol-, assay-, and cell-system-specific."],"prohibitedInferences":["Do not use this record as medical advice or as evidence that a disease can currently be treated safely with prime editing.","Do not generalize one experiment’s efficiency or off-target result to all prime editors, targets, tissues, or delivery systems."]},{"id":"urn:maha:record:repressilator-gene-oscillator","title":"Repressilator gene oscillator","recordKind":"concept","reviewState":"published-canonical","canonicalPath":"/knowledge/synthetic-biology/concepts/repressilator-gene-oscillator","contentHash":"sha256:67bd70ae51f2139f2dbacda76c3e0f42ea9585869a2717136a7d5a1305bcc748","claims":[{"id":"urn:maha:claim:repressilator-gene-oscillator","scope":"The constructs, biological systems, protocols, assays, datasets, and comparisons reported in A synthetic oscillatory network of transcriptional regulators.","boundary":"Observed oscillation period, regularity, burden, and persistence are tied to the construct, reporter, host, and environment.","claimKind":"empirical-claim","sourceIds":["source-elowitz-repressilator-2000"],"statement":"The cited study constructs a three-repressor oscillator in Escherichia coli and observes oscillatory fluorescent reporter behavior.","replication":{"asOfDate":"2026-08-24","assessment":"This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-elowitz-repressilator-2000","url":"https://www.nature.com/articles/35002125","title":"A synthetic oscillatory network of transcriptional regulators","rights":{"note":"Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Michael B. Elowitz","Stanislas Leibler"],"boundary":"The original oscillator’s dynamics are context-specific and do not establish robust timing across hosts, loads, environments, or scales.","publisher":"Nature","establishes":"The study constructs a three-repressor oscillatory network in Escherichia coli and reports oscillatory fluorescence behavior under specified constructs and conditions.","identifiers":[{"value":"10.1038/35002125","scheme":"doi"}],"publishedAt":"2000-01-20","exactLocator":"Abstract; Figures 1–5; model and single-cell fluorescence experiments."}],"boundaries":["Observed oscillation period, regularity, burden, and persistence are tied to the construct, reporter, host, and environment.","A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record."],"prohibitedInferences":["Do not treat the repressilator gene oscillator record as medical advice, a treatment recommendation, or evidence of general clinical readiness.","Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract."]},{"id":"urn:maha:record:editing-efficiency-and-byproduct-measurement","title":"Editing efficiency and byproduct measurement","recordKind":"measurement","reviewState":"published-canonical","canonicalPath":"/knowledge/synthetic-biology/measurements/editing-efficiency-and-byproduct-measurement","contentHash":"sha256:3cf0a8404838c04608f30227b2ceb5bdde2896c466aabe43e84294b2cfd96a8f","claims":[{"id":"urn:maha:claim:editing-efficiency-and-byproduct-measurement","scope":"The constructs, biological systems, protocols, assays, datasets, and comparisons reported in Search-and-replace genome editing without double-strand breaks or donor DNA.","boundary":"A headline efficiency without denominator, assay, detection threshold, byproduct taxonomy, biological replicate, and cell context is not portable.","claimKind":"empirical-claim","sourceIds":["source-anzalone-prime-2019-graph"],"statement":"The cited prime-editing study reports target- and condition-specific intended edits and byproducts using specified sequencing assays.","replication":{"asOfDate":"2026-08-24","assessment":"This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-anzalone-prime-2019-graph","url":"https://www.nature.com/articles/s41586-019-1711-4","title":"Search-and-replace genome editing without double-strand breaks or donor DNA","rights":{"note":"Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Andrew V. Anzalone","Peyton B. Randolph","Jessie R. Davis","Alexander A. Sousa","et al."],"boundary":"The study does not establish general delivery, organism-level safety, clinical benefit, or universal editing efficiency.","publisher":"Nature","establishes":"The study introduces a Cas9 nickase–reverse-transcriptase editor and prime-editing guide RNA architecture and reports specified edit classes in named cell systems.","identifiers":[{"value":"10.1038/s41586-019-1711-4","scheme":"doi"}],"publishedAt":"2019-10-21","exactLocator":"Abstract; Figures 1–5; Methods; Extended Data; Supplementary Tables 1–5.","conflictsOfInterest":"The article declares patent applications and company relationships involving genome editing."}],"boundaries":["A headline efficiency without denominator, assay, detection threshold, byproduct taxonomy, biological replicate, and cell context is not portable.","A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record."],"prohibitedInferences":["Do not treat the editing efficiency and byproduct measurement record as medical advice, a treatment recommendation, or evidence of general clinical readiness.","Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract."]},{"id":"urn:maha:record:single-cell-perturbation-readout","title":"Single-cell perturbation readout","recordKind":"measurement","reviewState":"published-canonical","canonicalPath":"/knowledge/synthetic-biology/measurements/single-cell-perturbation-readout","contentHash":"sha256:b9e71532d4dbfcd9ca6f0a343a4bbfb2714fffa715c8f0ddda5eb37b75afeeee","claims":[{"id":"urn:maha:claim:single-cell-perturbation-readout","scope":"The constructs, biological systems, protocols, assays, datasets, and comparisons reported in Perturb-Seq: Dissecting Molecular Circuits with Scalable Single-Cell RNA Profiling of Pooled Genetic Screens.","boundary":"Transcriptional state changes are assay- and model-dependent and do not alone prove direct mechanism or organism phenotype.","claimKind":"empirical-claim","sourceIds":["source-dixit-perturb-seq-2016"],"statement":"The cited Perturb-seq study connects CRISPR perturbations with single-cell RNA profiles in specified immune-cell experiments.","replication":{"asOfDate":"2026-08-24","assessment":"This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-dixit-perturb-seq-2016","url":"https://www.cell.com/cell/fulltext/S0092-8674(16)31610-5","title":"Perturb-Seq: Dissecting Molecular Circuits with Scalable Single-Cell RNA Profiling of Pooled Genetic Screens","rights":{"note":"Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Atray Dixit","Oren Parnas","Biyu Li","Jenny Chen","et al."],"boundary":"Transcriptomic association does not by itself establish direct mechanism, organism phenotype, safety, or therapeutic effect.","publisher":"Cell","establishes":"The study combines pooled CRISPR perturbations with single-cell RNA sequencing to resolve perturbation-associated transcriptional states in specified immune-cell experiments.","identifiers":[{"value":"10.1016/j.cell.2016.11.038","scheme":"doi"}],"publishedAt":"2016-12-15","exactLocator":"Summary; Figures 1–7; STAR Methods; supplementary tables and sequencing data."}],"boundaries":["Transcriptional state changes are assay- and model-dependent and do not alone prove direct mechanism or organism phenotype.","A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record."],"prohibitedInferences":["Do not treat the single-cell perturbation readout record as medical advice, a treatment recommendation, or evidence of general clinical readiness.","Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract."]},{"id":"urn:maha:record:targeted-amplicon-sequencing","title":"Targeted amplicon sequencing of edit outcomes","recordKind":"measurement","reviewState":"published-canonical","canonicalPath":"/knowledge/synthetic-biology/measurements/targeted-amplicon-sequencing","contentHash":"sha256:40ba97669b6d76a90b2075372a9bde9a598c97e6efb9da571db4b3b20efb7ad0","claims":[{"id":"urn:maha:claim:targeted-amplicon-sequencing","scope":"The constructs, biological systems, protocols, assays, datasets, and comparisons reported in GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases.","boundary":"Amplicon assays are limited by primer design, sampled sites, allele representation, read depth, error correction, and variant-calling thresholds.","claimKind":"empirical-claim","sourceIds":["source-tsai-guide-seq-2015"],"statement":"The cited GUIDE-seq workflow uses targeted sequencing and validation to characterize nominated cleavage sites under specified experiments.","replication":{"asOfDate":"2026-08-24","assessment":"This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-tsai-guide-seq-2015","url":"https://www.nature.com/articles/nbt.3117","title":"GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases","rights":{"note":"Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Shengdar Q. Tsai","Zongli Zheng","Nhu T. Nguyen","Matthew Liebers","et al."],"boundary":"GUIDE-seq has assay-specific detection limits and dependencies and does not nominate every possible off-target event in every biological context.","publisher":"Nature Biotechnology","establishes":"The study develops GUIDE-seq, a cell-based double-strand-break capture method, and applies it to specified nucleases and human cell lines.","identifiers":[{"value":"10.1038/nbt.3117","scheme":"doi"}],"publishedAt":"2014-12-16","exactLocator":"Abstract; Figures 1–6; Online Methods; Supplementary Tables; Sequence Read Archive SRP050338."}],"boundaries":["Amplicon assays are limited by primer design, sampled sites, allele representation, read depth, error correction, and variant-calling thresholds.","A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record."],"prohibitedInferences":["Do not treat the targeted amplicon sequencing of edit outcomes record as medical advice, a treatment recommendation, or evidence of general clinical readiness.","Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract."]},{"id":"urn:maha:record:double-strand-break-repair-outcomes","title":"Double-strand-break repair outcomes","recordKind":"mechanism","reviewState":"published-canonical","canonicalPath":"/knowledge/synthetic-biology/mechanisms/double-strand-break-repair-outcomes","contentHash":"sha256:3fdd54c8ac0ec168578662afd045fa07d499ed202d191e2f7fdcb1321715b7bf","claims":[{"id":"urn:maha:claim:double-strand-break-repair-outcomes","scope":"The constructs, biological systems, protocols, assays, datasets, and comparisons reported in Multiplex Genome Engineering Using CRISPR/Cas Systems.","boundary":"Repair distributions vary with cell state, locus, template, timing, delivery, assay, and selection and cannot be reduced to one universal outcome.","claimKind":"empirical-claim","sourceIds":["source-cong-multiplex-editing-2013"],"statement":"The cited mammalian-cell experiments report locus-specific indels and templated edits after CRISPR-Cas9 cleavage under defined conditions.","replication":{"asOfDate":"2026-08-24","assessment":"This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-cong-multiplex-editing-2013","url":"https://www.science.org/doi/10.1126/science.1231143","title":"Multiplex Genome Engineering Using CRISPR/Cas Systems","rights":{"note":"Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Le Cong","F. Ann Ran","David Cox","Shuailiang Lin","et al."],"boundary":"Cell-culture demonstrations do not establish organism-level delivery, clinical safety, durable benefit, or universal target performance.","publisher":"Science","establishes":"The study demonstrates CRISPR-Cas9 genome targeting and multiplex editing in mammalian cells under specified constructs, loci, delivery, and assays.","identifiers":[{"value":"10.1126/science.1231143","scheme":"doi"}],"publishedAt":"2013-01-03","exactLocator":"Abstract; Figures 1–4; supplementary methods and target-level results.","conflictsOfInterest":"The publisher record reports patent and company relationships involving CRISPR technologies."}],"boundaries":["Repair distributions vary with cell state, locus, template, timing, delivery, assay, and selection and cannot be reduced to one universal outcome.","A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record."],"prohibitedInferences":["Do not treat the double-strand-break repair outcomes record as medical advice, a treatment recommendation, or evidence of general clinical readiness.","Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract."]},{"id":"urn:maha:record:guide-rna-and-pam-recognition","title":"Guide RNA and PAM recognition","recordKind":"mechanism","reviewState":"published-canonical","canonicalPath":"/knowledge/synthetic-biology/mechanisms/guide-rna-and-pam-recognition","contentHash":"sha256:081073c605aee04950e56be34b76baf6419a1e11122e938f925900eb66c8042e","claims":[{"id":"urn:maha:claim:guide-rna-and-pam-recognition","scope":"The constructs, biological systems, protocols, assays, datasets, and comparisons reported in A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.","boundary":"Sequence recognition rules do not by themselves predict chromatin access, cellular activity, or every off-target interaction.","claimKind":"empirical-claim","sourceIds":["source-jinek-cas9-2012"],"statement":"The cited experiments show that guide sequence and adjacent motif requirements condition Cas9 binding and cleavage in the reconstructed system.","replication":{"asOfDate":"2026-08-24","assessment":"This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-jinek-cas9-2012","url":"https://www.science.org/doi/10.1126/science.1225829","title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","rights":{"note":"Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Martin Jinek","Krzysztof Chylinski","Ines Fonfara","Michael Hauer","Jennifer A. Doudna","Emmanuelle Charpentier"],"boundary":"An in-vitro nuclease mechanism does not establish editing efficiency, specificity, delivery, safety, or phenotype in cells or organisms.","publisher":"Science","establishes":"The study reconstitutes RNA-programmed Cas9 cleavage in vitro and shows that a designed single-guide RNA can direct sequence-specific DNA cleavage adjacent to an appropriate motif.","identifiers":[{"value":"10.1126/science.1225829","scheme":"doi"}],"publishedAt":"2012-06-28","exactLocator":"Abstract; Figures 1–5; supplementary materials describing guide design and cleavage assays."}],"boundaries":["Sequence recognition rules do not by themselves predict chromatin access, cellular activity, or every off-target interaction.","A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record."],"prohibitedInferences":["Do not treat the guide rna and pam recognition record as medical advice, a treatment recommendation, or evidence of general clinical readiness.","Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract."]},{"id":"urn:maha:record:prime-editing-guide-rna-mechanism","title":"Prime-editing guide RNA mechanism","recordKind":"mechanism","reviewState":"published-canonical","canonicalPath":"/knowledge/synthetic-biology/mechanisms/prime-editing-guide-rna-mechanism","contentHash":"sha256:566c8d24c285a007c6b350bde56eb4110e4766cda65e2d2de29a81796482f103","claims":[{"id":"urn:maha:claim:prime-editing-guide-rna-mechanism","scope":"The constructs, biological systems, protocols, assays, datasets, and comparisons reported in Search-and-replace genome editing without double-strand breaks or donor DNA.","boundary":"A pegRNA design does not predict universal efficiency, purity, delivery, or organism-level consequence.","claimKind":"empirical-claim","sourceIds":["source-anzalone-prime-2019-graph"],"statement":"The cited study demonstrates that pegRNA sequence elements and a nickase–reverse-transcriptase fusion jointly specify intended edit outcomes in named cell systems.","replication":{"asOfDate":"2026-08-24","assessment":"This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-anzalone-prime-2019-graph","url":"https://www.nature.com/articles/s41586-019-1711-4","title":"Search-and-replace genome editing without double-strand breaks or donor DNA","rights":{"note":"Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Andrew V. Anzalone","Peyton B. Randolph","Jessie R. Davis","Alexander A. Sousa","et al."],"boundary":"The study does not establish general delivery, organism-level safety, clinical benefit, or universal editing efficiency.","publisher":"Nature","establishes":"The study introduces a Cas9 nickase–reverse-transcriptase editor and prime-editing guide RNA architecture and reports specified edit classes in named cell systems.","identifiers":[{"value":"10.1038/s41586-019-1711-4","scheme":"doi"}],"publishedAt":"2019-10-21","exactLocator":"Abstract; Figures 1–5; Methods; Extended Data; Supplementary Tables 1–5.","conflictsOfInterest":"The article declares patent applications and company relationships involving genome editing."}],"boundaries":["A pegRNA design does not predict universal efficiency, purity, delivery, or organism-level consequence.","A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record."],"prohibitedInferences":["Do not treat the prime-editing guide rna mechanism record as medical advice, a treatment recommendation, or evidence of general clinical readiness.","Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract."]},{"id":"urn:maha:record:cell-free-gene-expression","title":"Cell-free gene expression systems","recordKind":"method","reviewState":"published-canonical","canonicalPath":"/knowledge/synthetic-biology/methods/cell-free-gene-expression","contentHash":"sha256:32cef5bd217860c38300140741a57a8bfed0d5b6f3838ed9fed17c2d5c14f958","claims":[{"id":"urn:maha:claim:cell-free-gene-expression","scope":"The constructs, biological systems, protocols, assays, datasets, and comparisons reported in A vesicle bioreactor as a step toward an artificial cell assembly.","boundary":"Cell-free expression does not imply self-replication, long-term autonomy, organism equivalence, containment, or scalable manufacturing.","claimKind":"empirical-claim","sourceIds":["source-noireaux-cell-free-2004"],"statement":"The cited study demonstrates gene expression inside fed lipid vesicles using a defined cell-free system.","replication":{"asOfDate":"2026-08-24","assessment":"This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-noireaux-cell-free-2004","url":"https://www.pnas.org/doi/10.1073/pnas.0408236101","title":"A vesicle bioreactor as a step toward an artificial cell assembly","rights":{"note":"Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Vincent Noireaux","Albert Libchaber"],"boundary":"A vesicle expression system is not a self-replicating cell and does not establish long-duration autonomy, evolution, containment, or manufacturing scale.","publisher":"Proceedings of the National Academy of Sciences","establishes":"The study demonstrates cell-free gene expression within lipid vesicles under a defined biochemical system and feeding arrangement.","identifiers":[{"value":"10.1073/pnas.0408236101","scheme":"doi"}],"publishedAt":"2004-12-21","exactLocator":"Abstract; Figures 1–5; Materials and Methods; expression and permeability experiments."}],"boundaries":["Cell-free expression does not imply self-replication, long-term autonomy, organism equivalence, containment, or scalable manufacturing.","A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record."],"prohibitedInferences":["Do not treat the cell-free gene expression systems record as medical advice, a treatment recommendation, or evidence of general clinical readiness.","Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract."]},{"id":"urn:maha:record:change-seq-off-target-nomination","title":"CHANGE-seq off-target nomination","recordKind":"method","reviewState":"published-canonical","canonicalPath":"/knowledge/synthetic-biology/methods/change-seq-off-target-nomination","contentHash":"sha256:639dd2d06cff8dcc160158834141a21736c46349819cbb20fcd1c3c7950f0d74","claims":[{"id":"urn:maha:claim:change-seq-off-target-nomination","scope":"The constructs, biological systems, protocols, assays, datasets, and comparisons reported in CHANGE-seq reveals genetic and epigenetic effects on CRISPR–Cas9 genome-wide activity.","boundary":"In-vitro cleavage nomination does not directly measure editing frequency or consequence in the intended cell product or organism.","claimKind":"empirical-claim","sourceIds":["source-lazzarotto-change-seq-2020"],"statement":"The cited study applies CHANGE-seq across many guides and compares nominations with cellular activity and genomic context.","replication":{"asOfDate":"2026-08-24","assessment":"This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-lazzarotto-change-seq-2020","url":"https://www.nature.com/articles/s41587-020-0555-7","title":"CHANGE-seq reveals genetic and epigenetic effects on CRISPR–Cas9 genome-wide activity","rights":{"note":"Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Christopher R. Lazzarotto","Nhu T. Nguyen","J. A. Tangprasertchai","S. C. Malagon-Lopez","et al."],"boundary":"In-vitro nomination is not identical to editing frequency or biological consequence in a treated cell population or organism.","publisher":"Nature Biotechnology","establishes":"The study develops an in-vitro circularized-DNA assay for Cas9 activity and compares nominations with cellular activity and genomic context for specified targets.","identifiers":[{"value":"10.1038/s41587-020-0555-7","scheme":"doi"}],"publishedAt":"2020-06-22","exactLocator":"Abstract; Figures 1–6; Methods; datasets PRJNA625995 and GSE149295.","conflictsOfInterest":"The article declares patent and company relationships involving genome-editing assays and therapeutics."}],"boundaries":["In-vitro cleavage nomination does not directly measure editing frequency or consequence in the intended cell product or organism.","A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record."],"prohibitedInferences":["Do not treat the change-seq off-target nomination record as medical advice, a treatment recommendation, or evidence of general clinical readiness.","Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract."]},{"id":"urn:maha:record:directed-evolution-workflows","title":"Directed-evolution workflows","recordKind":"method","reviewState":"published-canonical","canonicalPath":"/knowledge/synthetic-biology/methods/directed-evolution-workflows","contentHash":"sha256:40d200398e6ad545369316a84ca6ad0a584386c1f243df7d04bed0ec0f570613","claims":[{"id":"urn:maha:claim:directed-evolution-workflows","scope":"The constructs, biological systems, protocols, assays, datasets, and comparisons reported in A system for the continuous directed evolution of biomolecules.","boundary":"The selected trajectory depends on host, mutagenesis, linkage, passage, selection stringency, assay, and accessible sequence space.","claimKind":"empirical-claim","sourceIds":["source-esvelt-pace-2011"],"statement":"The cited PACE system links target activity to phage propagation and demonstrates continuous selection in a specified bacterial host system.","replication":{"asOfDate":"2026-08-24","assessment":"This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-esvelt-pace-2011","url":"https://www.nature.com/articles/nature09929","title":"A system for the continuous directed evolution of biomolecules","rights":{"note":"Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Kevin M. Esvelt","Jacob C. Carlson","David R. Liu"],"boundary":"Evolution trajectories and selected functions depend on host, linkage, mutagenesis, selection pressure, passage conditions, and assay definition.","publisher":"Nature","establishes":"The study introduces phage-assisted continuous evolution and demonstrates continuous selection of evolving biomolecular activity in specified bacterial systems.","identifiers":[{"value":"10.1038/nature09929","scheme":"doi"}],"publishedAt":"2011-04-10","exactLocator":"Abstract; Figures 1–4; Methods; selection and evolution experiments.","conflictsOfInterest":"The article declares patent interests involving the method."}],"boundaries":["The selected trajectory depends on host, mutagenesis, linkage, passage, selection stringency, assay, and accessible sequence space.","A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record."],"prohibitedInferences":["Do not treat the directed-evolution workflows record as medical advice, a treatment recommendation, or evidence of general clinical readiness.","Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract."]},{"id":"urn:maha:record:ex-vivo-genome-editing-workflow","title":"Ex-vivo genome-editing workflow","recordKind":"method","reviewState":"published-canonical","canonicalPath":"/knowledge/synthetic-biology/methods/ex-vivo-genome-editing-workflow","contentHash":"sha256:835c473a58c8114c35a25c88d3e618e1f2954e0555c8c29bd0d89db232111877","claims":[{"id":"urn:maha:claim:ex-vivo-genome-editing-workflow","scope":"The constructs, biological systems, protocols, assays, datasets, and comparisons reported in CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.","boundary":"The workflow’s risks and outcomes are indication-, cell-product-, conditioning-, manufacturing-, participant-, and follow-up-specific.","claimKind":"empirical-claim","sourceIds":["source-frangoul-crispr-2021"],"statement":"The cited report describes collection, ex-vivo CRISPR-Cas9 editing, conditioning, transplantation, and early follow-up for two participants.","replication":{"asOfDate":"2026-08-24","assessment":"This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-frangoul-crispr-2021","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2031054","title":"CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia","rights":{"note":"Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Haydar Frangoul","David Altshuler","M. Domenica Cappellini","Yi-Shan Chen","et al."],"boundary":"Two early cases do not establish population-level safety, durability, comparative effectiveness, or general readiness of genome editing.","publisher":"The New England Journal of Medicine","establishes":"The report describes ex-vivo CRISPR-Cas9 editing, conditioning, transplantation, and early clinical outcomes for two participants under a specific investigational protocol.","identifiers":[{"value":"10.1056/NEJMoa2031054","scheme":"doi"}],"publishedAt":"2020-12-05","exactLocator":"Abstract; Methods; Results; figures and tables for the two reported participants; supplementary protocol.","conflictsOfInterest":"The study was sponsored by CRISPR Therapeutics and Vertex Pharmaceuticals; author relationships are disclosed in the article."}],"boundaries":["The workflow’s risks and outcomes are indication-, cell-product-, conditioning-, manufacturing-, participant-, and follow-up-specific.","A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record."],"prohibitedInferences":["Do not treat the ex-vivo genome-editing workflow record as medical advice, a treatment recommendation, or evidence of general clinical readiness.","Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract."]},{"id":"urn:maha:record:genome-editor-delivery-systems","title":"Genome-editor delivery systems","recordKind":"method","reviewState":"published-canonical","canonicalPath":"/knowledge/synthetic-biology/methods/genome-editor-delivery-systems","contentHash":"sha256:142ae4fbdceaeeacd9dccb782d8e7f35a59cae6ac3a6153c4ab4e8d781137bbf","claims":[{"id":"urn:maha:claim:genome-editor-delivery-systems","scope":"The constructs, biological systems, protocols, assays, datasets, and comparisons reported in CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.","boundary":"One liver-targeted formulation does not establish delivery to other tissues, repeat dosing, long-term safety, or a general delivery platform.","claimKind":"empirical-claim","sourceIds":["source-gillmore-in-vivo-2021"],"statement":"The cited phase 1 study reports systemic lipid-nanoparticle delivery of Cas9 mRNA and guide RNA to hepatocytes under a named investigational protocol.","replication":{"asOfDate":"2026-08-24","assessment":"This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-gillmore-in-vivo-2021","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2107454","title":"CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis","rights":{"note":"Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Julian D. Gillmore","Ed Gane","Julian Taubel","Jingzhu Kao","et al."],"boundary":"Early biomarker and safety observations do not establish long-term clinical benefit, rare-event safety, or transfer to other tissues and targets.","publisher":"The New England Journal of Medicine","establishes":"The phase 1 report describes systemic lipid-nanoparticle delivery of CRISPR components and early dose-cohort biomarker and safety observations in adults with transthyretin amyloidosis.","identifiers":[{"value":"10.1056/NEJMoa2107454","scheme":"doi"}],"publishedAt":"2021-06-26","exactLocator":"Abstract; Methods; Results; Figures 1–3; supplementary protocol and statistical analysis.","conflictsOfInterest":"The study was funded by Intellia Therapeutics and Regeneron Pharmaceuticals; author relationships are disclosed."}],"boundaries":["One liver-targeted formulation does not establish delivery to other tissues, repeat dosing, long-term safety, or a general delivery platform.","A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record."],"prohibitedInferences":["Do not treat the genome-editor delivery systems record as medical advice, a treatment recommendation, or evidence of general clinical readiness.","Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract."]},{"id":"urn:maha:record:guide-seq-off-target-detection","title":"GUIDE-seq off-target detection","recordKind":"method","reviewState":"published-canonical","canonicalPath":"/knowledge/synthetic-biology/methods/guide-seq-off-target-detection","contentHash":"sha256:b738f5e6d5ec6fe626627038e22ded237d4b4def829b9460dcbb68e4da8b6c2e","claims":[{"id":"urn:maha:claim:guide-seq-off-target-detection","scope":"The constructs, biological systems, protocols, assays, datasets, and comparisons reported in GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases.","boundary":"Assay sensitivity depends on break capture, cell compatibility, sequencing, analysis, and the nuclease modality under study.","claimKind":"empirical-claim","sourceIds":["source-tsai-guide-seq-2015"],"statement":"The cited study develops GUIDE-seq and applies it to specified RNA-guided nucleases in two human cell lines.","replication":{"asOfDate":"2026-08-24","assessment":"This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-tsai-guide-seq-2015","url":"https://www.nature.com/articles/nbt.3117","title":"GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases","rights":{"note":"Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Shengdar Q. Tsai","Zongli Zheng","Nhu T. Nguyen","Matthew Liebers","et al."],"boundary":"GUIDE-seq has assay-specific detection limits and dependencies and does not nominate every possible off-target event in every biological context.","publisher":"Nature Biotechnology","establishes":"The study develops GUIDE-seq, a cell-based double-strand-break capture method, and applies it to specified nucleases and human cell lines.","identifiers":[{"value":"10.1038/nbt.3117","scheme":"doi"}],"publishedAt":"2014-12-16","exactLocator":"Abstract; Figures 1–6; Online Methods; Supplementary Tables; Sequence Read Archive SRP050338."}],"boundaries":["Assay sensitivity depends on break capture, cell compatibility, sequencing, analysis, and the nuclease modality under study.","A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record."],"prohibitedInferences":["Do not treat the guide-seq off-target detection record as medical advice, a treatment recommendation, or evidence of general clinical readiness.","Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract."]},{"id":"urn:maha:record:in-vivo-genome-editing-workflow","title":"In-vivo genome-editing workflow","recordKind":"method","reviewState":"published-canonical","canonicalPath":"/knowledge/synthetic-biology/methods/in-vivo-genome-editing-workflow","contentHash":"sha256:be7269de29ceb69f04304eac58a054460ee0d667332fa5cde126210fbffb52f9","claims":[{"id":"urn:maha:claim:in-vivo-genome-editing-workflow","scope":"The constructs, biological systems, protocols, assays, datasets, and comparisons reported in CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.","boundary":"Early dose-cohort observations do not establish long-term benefit, rare-event safety, repeatability, or transfer to another organ and target.","claimKind":"empirical-claim","sourceIds":["source-gillmore-in-vivo-2021"],"statement":"The cited phase 1 report describes systemic administration, dose cohorts, biomarker response, and early safety observations for a liver-targeted CRISPR intervention.","replication":{"asOfDate":"2026-08-24","assessment":"This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-gillmore-in-vivo-2021","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2107454","title":"CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis","rights":{"note":"Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Julian D. Gillmore","Ed Gane","Julian Taubel","Jingzhu Kao","et al."],"boundary":"Early biomarker and safety observations do not establish long-term clinical benefit, rare-event safety, or transfer to other tissues and targets.","publisher":"The New England Journal of Medicine","establishes":"The phase 1 report describes systemic lipid-nanoparticle delivery of CRISPR components and early dose-cohort biomarker and safety observations in adults with transthyretin amyloidosis.","identifiers":[{"value":"10.1056/NEJMoa2107454","scheme":"doi"}],"publishedAt":"2021-06-26","exactLocator":"Abstract; Methods; Results; Figures 1–3; supplementary protocol and statistical analysis.","conflictsOfInterest":"The study was funded by Intellia Therapeutics and Regeneron Pharmaceuticals; author relationships are disclosed."}],"boundaries":["Early dose-cohort observations do not establish long-term benefit, rare-event safety, repeatability, or transfer to another organ and target.","A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record."],"prohibitedInferences":["Do not treat the in-vivo genome-editing workflow record as medical advice, a treatment recommendation, or evidence of general clinical readiness.","Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract."]},{"id":"urn:maha:record:pooled-crispr-screening","title":"Pooled CRISPR screening","recordKind":"method","reviewState":"published-canonical","canonicalPath":"/knowledge/synthetic-biology/methods/pooled-crispr-screening","contentHash":"sha256:b5b4f2fe8862b93d6f65e0a66a98e8611e52e04c4bfe15981c2682714cdcda56","claims":[{"id":"urn:maha:claim:pooled-crispr-screening","scope":"The constructs, biological systems, protocols, assays, datasets, and comparisons reported in Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells.","boundary":"Guide enrichment identifies screen-dependent associations and can reflect editing, growth, delivery, copy number, sampling, and model-specific effects.","claimKind":"empirical-claim","sourceIds":["source-shalem-crispr-screen-2014"],"statement":"The cited study develops genome-scale CRISPR knockout libraries and reports positive and negative selection screens in specified human cell models.","replication":{"asOfDate":"2026-08-24","assessment":"This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-shalem-crispr-screen-2014","url":"https://www.science.org/doi/10.1126/science.1247005","title":"Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells","rights":{"note":"Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Ophir Shalem","Neville E. Sanjana","Ella Hartenian","Xi Shi","et al."],"boundary":"Screen enrichment is model-, library-, delivery-, coverage-, phenotype-, and analysis-specific and is not direct clinical or organism-level evidence.","publisher":"Science","establishes":"The study develops a pooled lentiviral CRISPR knockout library and applies positive and negative selection screens in specified human cell models.","identifiers":[{"value":"10.1126/science.1247005","scheme":"doi"}],"publishedAt":"2013-12-12","exactLocator":"Abstract; Figures 1–4; supplementary methods; library and screen-analysis sections."}],"boundaries":["Guide enrichment identifies screen-dependent associations and can reflect editing, growth, delivery, copy number, sampling, and model-specific effects.","A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record."],"prohibitedInferences":["Do not treat the pooled crispr screening record as medical advice, a treatment recommendation, or evidence of general clinical readiness.","Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract."]}],"withheldInventory":{"recordCount":1,"edgeCount":0,"recordKinds":{"hypothesis":1},"disclosure":"aggregate-only"},"boundary":"Only active canonical records are enumerated. Draft identifiers, titles, paths, claims, sources, and gate reasons remain private until canonical release."}